Paola Coco - Concepedia

Author

Paola Coco

Fondazione IRCCS Istituto Nazionale dei Tumori

Also Known As

COCO, Paola, P Coco, P. COCO, P. Coco, Paola Coco

Publications

875

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori European Institute of Oncology Bayer (Germany)Helsinki University Hospital Novartis (Italy)

About

Paola Coco is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	217
2	Gastroenterology	2	2	33
3	Public Health	1	1	12
4	Health Policy	1	1	12
5	Immunology	1	1	12

Paola Coco

Publications

804

Citations

H-Index

Page 1

	Year	Citations
Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST Alessandro Gronchi, Marco Fiore, Francesca Miselli, Annals of Surgery	2007	245
A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake Deborah Mannavola, Paola Coco, Guia Vannucchi, The Journal of Clinical Endocrinology & Metabolism	2007	225
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study Heikki Joensuu, Filippo de Braud, G Grignagni, British Journal of Cancer	2011	77
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate Heikki Joensuu, Filippo de Braud, Paola Coco, Annals of Oncology Phase IiGastrointestinal OncologyMedicinePathologyColorectal Cancer	2007	62
Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib Antoîne Italiano, Angela Cioffi, Paola Coco, Annals of Surgical Oncology Gastrointestinal OncologyMedicinePathologyGastrointestinal Stromal TumorsFirst-line Imatinib	2011	60
Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma Pier Francesco Ferrucci, Ida Minchella, Massimo Mosconi, Melanoma Research OncologyBraf MutationMedicineMelanomaImmune Checkpoint Inhibitor	2015	25
Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study Palma Dileo, Sabrina Pricl, Elena Tamborini, International Journal of Cancer	2010	19
A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate Heikki Joensuu, Filippo de Braud, Paola Coco, Journal of Clinical Oncology GastroenterologyPathologyPharmacotherapyMetronomic ChemotherapyOncology	2006	18
Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) Alessandro Gronchi, Marco Fiore, Rossella Bertulli, Journal of Clinical Oncology Residual DiseaseImatinib TherapySurgical OncologyGastrointestinal OncologyMedicine	2005	15
Combination of PKC412 and sirolimus in a metastatic patient with PDGFRA-D842V gastrointestinal stromal tumor (GIST) Elena Palassini, Elena Fumagalli, Paola Coco, Journal of Clinical Oncology PathologyTumor BiologyOncologyGastrointestinal OncologyMetronomic Therapy	2008	13

Page 1